抗体药物偶联物在实体瘤治疗中的突破与毒性管理
摘要
关键词
全文:
PDF镜像
|参考
Tarantino P, Ricciuti B, Pradhan M, et al. Optimizing the safety of antibody-drug conjugates in solid tumors. Nat Rev Clin Oncol. 2025;22(8):521-538.
Ferraro E, Drago JZ, Modi S. Implementing antibody-drug conjugates in solid tumors: from preclinical advances to clinical practice. Cancer Cell. 2026;44(2):210-229.
Conlon NT, Kooijman JJ, van Gerwen SJC, et al. The pharmacology of antibody-drug conjugates: from mechanisms to management. Pharmacol Rev. 2026;78(1):100055.
Dumontet C, Reichert JM, Senter PD, et al. Antibody-drug conjugates come of age in oncology. Nat Rev Drug Discov. 2025;24(6):401-424.
Powell CA, Modi S, Iwata H, et al. Management of interstitial lung disease associated with trastuzumab deruxtecan: a clinical practice guide. J Clin Oncol. 2025;43(15):1812-1823.
Wang Y, Liu B, Zhang H, et al. Probody-drug conjugates: a new frontier for tumor-selective delivery. Adv Drug Deliv Rev. 2026;210:115334.
Rinnerthaler G, Gampenrieder SP, Greil R. HER2-low breast cancer: a new entity and implications for ADC therapy. ESMO Open. 2025;10(4):104235.
Spring LM, O’Shaughnessy JA, Hamilton EP, et al. Next-generation antibody-drug conjugates: dual-payload and bispecific approaches. Cancer Discov. 2026;16(3):480-497.
Hurvitz SA, Baselga J, Cortés J, et al. Trastuzumab deruxtecan in HER2-positive metastatic breast cancer: long-term efficacy and safety update. N Engl J Med. 2025;392(19):1889-1902.
Masters JC, Krop IE. Mitigating off-target toxicities of antibody-drug conjugates through Fc engineering. MAbs. 2026; 18(1):e2457893.
(0 摘要 Views, 0 PDF Downloads)
Refbacks
- 当前没有refback。